UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049071
Receipt number R000055907
Scientific Title Effects of imeglimin in patients with type 2 diabetes mellitus
Date of disclosure of the study information 2022/10/01
Last modified on 2022/09/30 11:31:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of imeglimin in patients with type 2 diabetes mellitus

Acronym

Effects of imeglimin in patients with type 2 diabetes mellitus

Scientific Title

Effects of imeglimin in patients with type 2 diabetes mellitus

Scientific Title:Acronym

Effects of imeglimin in patients with type 2 diabetes mellitus

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Medicine in general Endocrinology and Metabolism Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To study the effect of imeglimin on various parameters in patients with type 2 diabetes mellitus.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood glucose and skeletal muscle related parameters

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with type 2 diabetes attending the Department of Diabetes and Metabolism
HbA1c between 7.0% and 10%.
Patients with written consent

Key exclusion criteria

Patients with a history of severe ketoacidosis, diabetic coma, or pre-coma
Patients with malignant tumors and other serious diseases with poor prognosis
Impaired renal function: eGFR <45 mL/min/1.73 m2

Target sample size

30


Research contact person

Name of lead principal investigator

1st name satoshi
Middle name
Last name ida

Organization

Ise Red Cross Hospital

Division name

Department of diabetes and metabolism

Zip code

516-8512

Address

1-471-2, Funae, 1-chome

TEL

0596282171

Email

bboy98762006@yahoo.co.jp


Public contact

Name of contact person

1st name satoshi
Middle name
Last name ida

Organization

Ise Red Cross Hospital

Division name

Department of diabetes and metabolism

Zip code

516-8512

Address

1-471-2, Funae, 1-chome

TEL

0596282171

Homepage URL


Email

bboy98762006@yahoo.co.jp


Sponsor or person

Institute

Ise Red Cross Hospital

Institute

Department

Personal name



Funding Source

Organization

Ise Red Cross Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics committee of Ise Red Cross Hospital

Address

1-471-2, Funae, 1-chome, Ise-shi, Mie, 516-8512

Tel

0596282171

Email

bboy98762006@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 10 Month 01 Day

Date of IRB

2022 Year 09 Month 30 Day

Anticipated trial start date

2022 Year 10 Month 01 Day

Last follow-up date

2023 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2022 Year 09 Month 30 Day

Last modified on

2022 Year 09 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055907


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name